report adjust ep in-lin consensu
expect estim revenu exceed
top end compani guidanc million
commensur increas expens provid off-set
zbh revenu increas year-over-year million
consensu million estim
million better-than-anticip orthoped market growth main
contributor zbh revenu out-performance addit compani
experienc strong order asia pacif stock distributor million
contribut revenu upsid
expect adjust ep versu prior consensu
expect revenu million versu consensu
expect million organ growth neg includ
impact one less sell day year-over-year free cash flow
million addit sale day chang step-down zbh
organ growth guidanc reflect expect softer
pacif growth given time distributor order slower growth
unit kingdom due nh delay elect procedur januari
februari free hospit bed patient influenza
provid color regard outlook includ expect
adjust gross margin million increment performance-
base compens expens tax rate million
save tax reform reinvest back busi effort
drive near-term organ growth provid full guidanc
compani new ceo bryan hanson suggest see risk
opportun relat zbh prior target key product launch time
return full product suppli addit believ
delay translat full suppli sale recoveri compani sale
repres need gain comfort suppli realli back
start aggress target competit account overal expect
gradual revenu recoveri
total debt total asset
reduc adjust ep estim
single-digit improv outlook appear lacklust
upcom event includ expect fda re-inspect biomet warsaw
manufactur facil potenti preview upcom product launch
march american academi orthopaed surgeon aao annual
meet provid opportun catalyst point view risk/reward
balanc maintain neutral rate
import pleas read disclosur disclaim page report
report adjust ep in-lin consensu expect
estim mid-point zbh guidanc rang revenu exceed
top end compani guidanc million commensur increas expens
provid off-set
zbh revenu increas year-over-year million consensu expect
million estim million compani guidanc rang million
quarter achiev organ growth neg flat guidanc better-than-
anticip orthoped market growth main contributor zbh revenu out-performance
addit compani experienc strong order asia pacif stock distributor million contribut
revenu upsid dental product sale also exceed zbh expect
adjust incom statement revenu growth analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom margin com share compani report northcoast research estim
product categori standpoint five zbh orthoped busi segment exceed organ
growth forecast led rel flat combin america hip knee implant organ growth well
neg forecast expect rebound hip knee implant organ growth
least low end tradit rang follow orthoped practic survey zbh data
suggest market growth toward high end rang moreov zbh domest market share much
better anticip stronger market off-set weak depuy knee
knee post organ growth neg neg estim
state previous main differ versu expect magnitud improv zbh
america knee busi rebound neg organ growth versu organ growth
declin zbh emea knee busi also post stronger sequenti perform knee organ
growth asia pacif declin mid-single-digit rate reflect larg year-over-year price reduct india
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast researchnorthcoastreportedrevenu currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim total zbh knee price growth declin year-over-year decreas last quarter
notabl also discuss modestli weaker orthoped price trend chalk ebb
flow market well larg knee implant price chang india
continu believ product suppli product gap drive market share loss knee regard
product gap compani continu expect launch persona trabecular metal cementless tibia
persona revis knee rosa total knee applic also slate limit launch back half
year limit launch last roughli month like mean zbh knee implant busi
continu grow market rate anoth six quarter even address suppli issu complet
product launch in-lin forecast
hip post posit organ growth meaning neg forecast
similar knee zbh hip organ growth aid much stronger sequenti perform america
posit organ growth versu organ growth decreas compani
estim market grew roughli addit zbh asia pacif hip implant sale particularli
strong organ versu closer organ growth prior three quarter like aid
time order stock distributor favor result two geographi help off-set
declin organ growth zbh emea hip implant busi post weakest result year
moreov similar knee overal busi zbh hip price growth declin sequenti quarter
year-over-year versu decreas
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast
zbh adjust oper margin declin bp year-over-year
forecast quarter higher adjust sg expens account differ versu estim
compani increas invest sale channel experienc unexpect cost prepar
implement tax reform adjust gross margin bp year-over-year similar
zbh guidanc rang lower price growth year-over-year versu decreas
first nine month year weigh perform along step-up manufactur cost
product produc biomet warsaw facil continu impact year-over-year gross margin
perform
expect adjust ep versu prior consensu expect revenu
million versu consensu expect million organ growth neg
includ impact one less sell day year-over-year free cash flow million addit
sale day chang step-down zbh organ growth guidanc reflect expect softer
 orthoped market growth follow rel strong weaker asia pacif growth given time
inc hip organ growth analysi reflect pro forma result zimmer biomet compani report northcoast inc quarterli total compani price growth year-over-year compani distributor order slower growth unit kingdom due nh delay elect procedur januari
februari free hospit bed patient influenza
provid color regard outlook includ expect adjust gross margin
million increment performance-bas compens expens tax rate million
save tax reform reinvest back busi effort drive near-term organ growth
provid full guidanc compani new ceo bryan hanson suggest see risk
opportun relat zbh prior target key product launch time return full product suppli
addit believ delay translat full suppli sale recoveri compani sale
repres need gain comfort suppli realli back start aggress target
competit account overal expect gradual revenu recoveri
overal reduc adjust ep estim revis outlook assum flat
organ growth includ low-single-digit improv outlook appear lacklust
upcom event includ expect fda re-inspect biomet warsaw manufactur facil
potenti preview upcom product launch march american academi orthopaed surgeon
aao annual meet provid opportun catalyst point view risk/reward
balanc maintain neutral rate
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth exclud amort intang asset adjust ep start compani report northcoast research estim disclosur
